Form 4: Zivo Bioscience Director Nola E. Masterson Reports Changes in Beneficial Ownership

Director Nola E. Masterson reports transactions involving Zivo Bioscience stock, including the acquisition of restricted stock and cancellation of stock options.

Summary

• On June 5, 2024, Nola E. Masterson, a director of Zivo Bioscience, Inc., reported changes in beneficial ownership of the company's stock.
• Masterson acquired 30,010 shares of common stock and 84,941 shares of common stock at $7.96.
• Masterson also disposed of 30,876 shares of common stock.
• These transactions resulted in Masterson beneficially owning 115,817 shares of common stock following the reported transactions.
• Additionally, Masterson disposed of nonstatutory stock options to purchase common stock at various exercise prices, including $26.88, $33, $21.66, $17.16, and $16.74.
• The options were canceled in exchange for the restricted stock.
• The share amount and exercise price have been adjusted from the amount reported on a previous Form 4 to reflect a 1 for 6 reverse stock split of the Issuer's stock in October 2023.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the document primarily reports transactions without expressing a clear positive or negative outlook. The acquisition of shares could be seen as positive, but the disposal and option cancellations temper this view.

Positives

• Masterson's acquisition of 30,010 shares of restricted stock and 84,941 shares of common stock could be interpreted as a sign of confidence in the company's future prospects.

Negatives

• The disposal of 30,876 shares of common stock and the cancellation of stock options could be seen as a negative signal, although it's explained as part of a transaction to receive restricted stock.

Risks

• The transactions are complex and involve the cancellation of options and the acquisition of restricted stock, which may require further analysis to fully understand the implications.
• The reverse stock split in October 2023 may have impacted investor sentiment and the perceived value of the stock.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors for signals about management's confidence in the company.

Comparison to Industry Standards

• Comparing Masterson's transactions to those of other directors in similar biotech companies could provide context on whether these actions are typical or indicative of a specific trend.
• Analyzing the vesting schedules and terms of the canceled stock options against industry norms can help assess the fairness of the exchange for restricted stock.
• Benchmarking Zivo Bioscience's stock performance against its peers after the reverse stock split can reveal how the market has perceived the company's financial health.

Stakeholder Impact

• Shareholders may be interested in these transactions as they provide insight into the actions of a key company insider.
• Employees holding stock options may be affected by changes in the company's stock price and option terms.

Key Dates

Keywords

Zivo Bioscience, Masterson, Beneficial Ownership, Stock Options, Restricted Stock, Form 4, Director, Transactions